Alexis Practical Tactical ETF LEXI 深 滬
已收盤 09-19 16:00:00 美东时间
34.5189
+0.112
+0.33%
華盛通- 最 高34.5189
- 今 開34.4408
- 成交量 696股
- 最 低 34.43
- 昨 收 34.4065
- 總市值 1.29亿
- 52周最高 34.5189
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 26.055
- 委 比 0.00%
- 總股本 372.68万
- 歷史最高 34.5189
- 量 比 0.14
- 振 幅 0.26%
- 歷史最低 19.983
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ramaco Announces New Senior Management Hire
LEXINGTON, Ky., Sept. 18, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB, "Ramaco" or the "Company") Ramaco is pleased to announce that it has hired Joseph M. Stopper as Se...
09-18 20:04
Ramaco Resources Announces Third Quarter Class B Stock Dividend Details
LEXINGTON, Ky., Sept. 8, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB, "Ramaco" or the "Company") a leading operator and developer of high-quality, low-cost metallurgical...
09-09 04:05
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Lexicon Pharmaceuticals, Inc. announced that its management will participate in fireside chats at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright Global Investment Conference on September 8 at 3:00 p.m. ET. The live events and replays can be accessed via the Company’s website. Lexicon, a biopharmaceutical company, focuses on pioneering medicines through its Genome5000 program, targeting disease...
08-27 12:30
Keros Therapeutics Reveals The FDA Granted Orphan Drug Designation For KER-065 For The Treatment Of Duchenne Muscular Dystrophy
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a
08-20 21:50
Keros Therapeutics Announces Strategic Realignment To Reallocate Resources Towards Development Of Its Key Clinical Program, KER-065; Discontinues Development of Cibotercept (KER-012)
Company Discontinuing Development of Cibotercept (KER-012)Announces Board and Leadership Changes Designed to Support Streamlined Operational Structureand Strategic RealignmentLEXINGTON, Mass., Aug. 06, 2025 (GLOBE
08-07 04:59
Valvoline Inc. Reports Third Quarter Results
Delivers sales of $439 million with strong profit growth; Adds 46 new stores LEXINGTON, Ky., Aug. 6, 2025 /PRNewswire/ -- Valvoline Inc. (NYSE: VVV), the quick, easy, trusted leader in prev...
08-06 19:00
Curis Provides Second Quarter 2025 Business Update
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the develop...
08-05 20:00
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals announced they will release their second quarter 2025 financial results on August 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET. The webcast and archived version will be available on their website.
07-23 12:00
Valvoline Inc. Releases Its Fiscal Year 2024 Impact Report
LEXINGTON, Ky., July 15, 2025 /PRNewswire/ -- Valvoline Inc. (NYSE: VVV), the quick, easy, trusted leader in preventive automotive maintenance, today announced the release of its Impact Repo...
07-15 19:00
Update on Independent Preliminary Economic Assessment Report from Fluor Corporation
LEXINGTON, Ky., July 8, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB) ("Ramaco" or the "Company") announces that on July 9 it will receive the Preliminary Economic Assess...
07-09 04:30
